

Appl. No. : 10/719,619
Filed : November 20, 2003

AMENDMENTS TO THE SPECIFICATION

Please replace the section entitled "CROSS-REFERENCE TO RELATED APPLICATIONS" with the following:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application number 10/104,966 filed on March 22, 2002, now issued as U.S. Patent No. 6,680,059, which is a continuation of U.S. patent application number 09/705,547 filed on November 3, 2000, now abandoned, both of which claim the benefit of priority of U.S. provisional patent application number 60/229,175, filed August 29, 2000. The aforementioned applications are hereby expressly incorporated by reference in their entireties.

Please replace the paragraph beginning at page 8, line 30, with the following:

As shown in FIGURE 3 [[2]], mice that were immunized with 100µg rNS3 mixed with 1mg Ribavirin had a much greater T cell proliferative response than mice that were immunized with 100µg rNS3 in PBS. This data provides evidence that Ribavirin can enhance a cellular immune response (e.g., by promoting the effective priming of T cells).